Sunday 11 October 2026
Export all LLY data to Excel Powerpack
Eli Lilly and Company
LLY Healthcare Drug Manufacturers General
Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024. In the quarter to June 2026, revenue grew 47.7%, EPS grew 26.2%, free cash flow grew 458.1% and total debt rose 37.6%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years, revenue growth for five.
1,179.27
9.67
+0.83%
Follow LLY
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
40.25 | 32.67 | 46.83 | 37.33 |
+8 more quarters Free account |
P/S ratio |
13.44 | 11.39 | 14.79 | 11.52 | |
P/FCF ratio |
52.49 | 58.67 | 86.31 | 59.65 | |
P/Operating CF |
100.13 | 154.27 | 299.05 | 77.45 | |
P/B ratio |
31.59 | 26.37 | 36.34 | 28.69 | |
Price to Tangible BV |
154.68 | 46.50 | 68.31 | 59.48 | |
EV/Sales |
14.01 | 11.88 | 15.34 | 12.13 | |
EV/EBITDA |
31.24 | 25.58 | 35.32 | 29.38 | |
EV/Operating CF |
39.75 | 41.92 | 59.45 | 44.89 | |
EV/FCF |
54.75 | 61.21 | 89.46 | 62.85 | |
Quick Ratio |
0.68 | 0.72 | 0.78 | 0.73 | |
Current Ratio |
1.35 | 1.50 | 1.58 | 1.55 | |
Net Debt/EBITDA |
4.83 | 3.62 | 3.93 | 3.95 | |
Debt/Assets |
38.59% | 33.77% | 37.79% | 35.56% | |
Debt/Equity |
1.62 | 1.26 | 1.60 | 1.71 | |
Asset Turnover |
0.66 | 0.70 | 0.68 | 0.62 | |
Operating CF/Net income |
1.51 | 0.72 | 0.49 | 1.58 | |
Capex/Depreciation |
(5.49) | (4.57) | (4.35) | (4.44) | |
Research and Development Expense of Revenue |
16.62% | 17.73% | 19.70% | 19.69% | |
Selling, General and Administrative Expense of Revenue |
14.93% | 14.82% | 16.24% | 15.57% | |
Intangible Assets out of Total Assets |
0.19 | 0.12 | 0.11 | 0.11 | |
Share Based Compensation of Revenue |
0.87% | 0.81% | 0.71% | 0.86% | |
Graham Net Nets |
(0.04) | (0.04) | (0.03) | (0.04) | |
Graham Number |
159.55 | 148.63 | 123.57 | 110.59 | |
Earnings Yield |
2.48% | 3.06% | 2.14% | 2.68% | |
Free Cash Flow Yield |
1.91% | 1.70% | 1.16% | 1.68% | |
Revenue per Share |
25.74 | 22.13 | 21.50 | 19.62 | |
Operating CF per Share |
11.98 | 5.96 | 3.59 | 9.85 | |
Capex per Share |
(3.29) | (2.60) | (2.84) | (2.33) | |
Free Cash Flow per Share |
8.69 | 3.36 | 0.76 | 7.52 | |
Cash per Share |
10.03 | 5.91 | 8.10 | 11.05 | |
Shareholders Equity per Share |
37.96 | 34.88 | 29.57 | 26.59 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
37.96 | 34.88 | 29.57 | 26.59 | |
Free Cash Flow |
7,757.00 | 3,007.00 | 677.90 | 6,748.10 | |
Working Capital |
16,931.00 | 18,201.00 | 20,401.00 | 21,930.40 | |
Capital Expenditures |
(2,933.00) | (2,326.00) | (2,546.70) | (2,087.30) | |
Net Current Asset Value |
(43,732.00) | (30,543.00) | (30,312.00) | (29,013.30) | |
EV/EBIT |
33.19 | 27.23 | 38.00 | 31.85 | |
Capex to Sales |
0.13 | 0.12 | 0.13 | 0.12 | |
Price to Operating Income |
31.83 | 26.10 | 36.66 | 30.23 | |
| Other line items | |||||
Average Receivables |
20,340.30 | 17,590.10 | 16,715.50 | 15,754.45 | |
Average Payables |
5,093.85 | 4,235.50 | 4,304.00 | 3,574.35 | |
Average Inventory |
13,903.40 | 11,920.00 | 10,666.50 | 9,820.10 | |
Average Assets |
121,602.80 | 102,982.40 | 95,595.50 | 95,271.15 | |
Average Common Equity |
26,114.05 | 23,522.40 | 20,403.50 | 19,085.75 |
Columns are period end dates